Figure 1D confirmed this and showed that increased MTDH was particularly prevalent in the MMSET-activating translocations subgroup (MS) compared to other 7 subgroups in TT2 cohort, which is one of the subgroups with the poorest prognosis in MM (p<0.0001, one-way ANOVA, Fig. 1D) [5]. Here, NSD2 is linked to Miyoshi myopathy.